Notebookcheck Logo

D-Pocket personal non-invasive blood glucose monitor from DiaMonTech attracts substantial investment from Samsung Ventures

The D-Pocket non-invasive blood glucose monitor only requires the user to put their finger on the sensor. (Image source: DiaMonTech - edited)
The D-Pocket non-invasive blood glucose monitor only requires the user to put their finger on the sensor. (Image source: DiaMonTech - edited)
The German company DiaMonTech has secured over US$20 million in funding to help it with device miniaturization and US expansion. The firm wants to offer its pocket-sized non-invasive blood glucose monitor, the D-Pocket, to people with either type 1 or type 2 diabetes as an accurate alternative to invasive methods.

DiaMonTech has received millions of dollars in funding from venture capital firms as it makes progress with its non-invasive blood glucose monitoring technology and hardware. Even Samsung Ventures, which is a division of the famous multinational Samsung Electronics, has shown interest in DiaMonTech’s D-Pocket monitor and has invested in the healthtech firm. The Investment Director from Samsung Ventures stated, “We are excited to invest in DiaMonTech, a pioneer in non-invasive health monitoring.”

Numerous firms are working on non-invasive and pain-free methods of glucose measurement that do away with lancets and test strips, with DiaMonTech working on three separate solutions of its own. These are the D-Base, which has been used in clinical trials and is the size of a shoebox, the D-Sensor that can be incorporated as a continuous glucose monitor into a wearable such as a smartwatch, and the aforementioned D-Pocket. The latter hardware could be on the market by 2023 as long as it gets FDA approval for use in the US.

The D-Pocket non-invasive glucose monitor looks like a small smartphone-type of device and simply involves the user placing their finger on the sensor. DiaMonTech relies on molecular spectroscopy for measuring glucose levels, so the device uses a red-light laser that causes the glucose molecules in the interstitial fluid to give off heat, which can then be measured. Apparently, in a clinical study held back in 2019, DiaMonTech’s system delivered very encouraging “99.1% precise measurement results”.

No price for the D-Pocket has been published yet as it is still in the development stage. However, securing millions of dollars of funding and attracting a household name such as Samsung can only be seen as positives for DiaMonTech’s future in regard to producing an acceptable non-invasive glucose monitor. There are no disposable parts and the D-Pocket is, as its name suggests, small enough to carry around in a pocket or small bag.

Buy Contour Next blood glucose test strips from Amazon

The D-Base, D-Pocket, and D-Sensor. (Image source: DiaMonTech)
The D-Base, D-Pocket, and D-Sensor. (Image source: DiaMonTech)


DiaMonTech (1/2) & YouTube

DiaMonTech attracts $5 million from Samsung Ventures and U.S.-based venture capitalists to bring its new non-invasive glucose monitor to the U.S.

  • Total funding for DiaMonTech is now more than $20 million
  • The new investors — Samsung Ventures, U.S.-based Unorthodox Ventures, Germany-based Golden Light, and a global medical technology company — join the existing participating investors around IBB Ventures
  • The additional funding will support DiaMonTech to expedite miniaturization of its existing device and finance expansion to the U.S.

BERLIN — Feb. 17, 2022 — DiaMonTech, an award-winning medical technology start-up pioneering non-invasive blood glucose measurements, today announced a $5 million investment round, bringing its total funding to over $20 million. Adding Samsung Ventures and a global medical technology company as strategic partners reaffirms DiaMonTech’s ambition to revolutionize non- invasive diabetes management.

DiaMonTech’s goal is to globally provide people living with diabetes with a ground-breaking technology for managing blood glucose levels without finger pricking, needles and test strips. The patented mid-infrared technology enables non-invasive blood glucose measurement using a pain-free laser-based detection that is as easy to use as the fingerprint sensor on a smartphone.

The new funds will accelerate DiaMonTech’s product development and enable its international expansion to the U.S. taking advantage of growing interest in the company’s first portable product — the “D-Pocket.”

“We are delighted to welcome Samsung Ventures as strategic partner to this financing round along with Unorthodox Ventures, Golden Light and the existing shareholders around IBB Ventures. Our investors have backed a wave of revolutionary tech companies. Their commitment to DiaMonTech is a vote of confidence in our team and technology,” said Thorsten Lubinski, CEO of DiaMonTech.

“Samsung Venture Investment’s mission is to accelerate the discovery and development of new businesses and technologies including Digital Health. We are excited to invest in DiaMonTech, a pioneer in non-invasive health monitoring,” the Samsung Ventures Investment Director said.

“We are very happy with the progress made by DiaMonTech in the last years and are getting closer and closer to a commercial product. The new funding and the new strategic investors enable DiaMonTech to become a global player in diabetes,” said Christian Seegers, Senior Investment Manager at IBB Ventures.

“Diabetes is a major problem globally. At Unorthodox Ventures, we are interested in technologies that help people manage their health without medications. We are delighted to partner with DiaMonTech, which has developed this impressive innovation for people to more proactively manage their diabetes and overall health,” said Carey Smith, Founding Contrarian of Unorthodox Ventures.

About DiaMonTech

Founded in Berlin, Germany, in 2015, DiaMonTech is a medical technology company committed to improving health outcomes for people with diabetes and empowering them to take control of their lifelong health. Its pioneered and patented non-invasive “no prick” photothermal detection technology is fast and painless and doesn’t require needles or test strips. An industry first, DiaMonTech monitors the actual glucose molecules in skin, providing users with a more comprehensive and accurate reading comparable to invasive commercial devices. DiaMonTech achieved 99.1% accuracy in a test study with 100 people studied, received the CE mark as a medical device in April 2019 and is currently under FDA review. To support its mission, DiaMonTech is led by a world-class team of scientists, researchers and healthcare experts.

Read all 1 comments / answer
static version load dynamic
Loading Comments
Comment on this article
Please share our article, every link counts!
> Expert Reviews and News on Laptops, Smartphones and Tech Innovations > News > News Archive > Newsarchive 2022 03 > D-Pocket personal non-invasive blood glucose monitor from DiaMonTech attracts substantial investment from Samsung Ventures
Daniel R Deakin, 2022-03- 4 (Update: 2022-03- 4)